Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies

Yujiro Takae, Takeji Nishikawa, Masayuki Amagai

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pemphigus vulgaris (PV) is an autoimmune bullous disease caused by immunoglobulin G (IgG) autoantibodies against desmoglein 3 (Dsg3). We have generated an active disease mouse model for PV by adoptive transfer of Dsg3-/- lymphocytes. In this study, we investigated the benefits and limitations of this model as a tool to evaluate various immunosuppressive therapeutic strategies. We used the following three measurements to evaluate the effects of the drugs during the time course: Dsg3 enzymelinked immunosorbent assay scores that represent the level of production of anti-Dsg3 IgG, body weight loss that reflects the severity of oral erosions and PV score that reflects the extent of skin lesions. We examined various immunosuppressive agents currently used to treat patients with PV model mice in preventive protocol. Cyclophosphamide almost completely suppressed the production of anti-Dsg3 IgG, development of body weight loss and the appearance of the PV phenotype in contrast with the control group without the drug. Azathioprine, cyclosporin A and tacrolimus hydrate also showed suppressive effects to various degrees. However, methylprednisolone and dexamethasone failed to show significant effects in contrast to the findings reported in humans. Knowing the advantages and limitations of this model will provide an important foundation for the future evaluation and development of novel therapeutic strategies.

Original languageEnglish
Pages (from-to)252-260
Number of pages9
JournalExperimental Dermatology
Volume18
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Desmoglein 3
Pemphigus
Immunosuppressive Agents
Immunoglobulin G
Weight Loss
Body Weight
Therapeutics
Immunosorbents
Lymphocytes
Adoptive Transfer
Methylprednisolone
Azathioprine
Tacrolimus
Hydrates
Pharmaceutical Preparations
Autoantibodies
Cyclophosphamide
Dexamethasone
Cyclosporine
Autoimmune Diseases

Keywords

  • Autoantibody
  • Evaluation
  • Immunosuppressive therapy
  • Mouse model
  • Pemphigus vulgaris

ASJC Scopus subject areas

  • Dermatology
  • Molecular Biology
  • Biochemistry

Cite this

Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies. / Takae, Yujiro; Nishikawa, Takeji; Amagai, Masayuki.

In: Experimental Dermatology, Vol. 18, No. 3, 2009, p. 252-260.

Research output: Contribution to journalArticle

@article{af5c9538ebfe49469ec521f909d942f4,
title = "Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies",
abstract = "Pemphigus vulgaris (PV) is an autoimmune bullous disease caused by immunoglobulin G (IgG) autoantibodies against desmoglein 3 (Dsg3). We have generated an active disease mouse model for PV by adoptive transfer of Dsg3-/- lymphocytes. In this study, we investigated the benefits and limitations of this model as a tool to evaluate various immunosuppressive therapeutic strategies. We used the following three measurements to evaluate the effects of the drugs during the time course: Dsg3 enzymelinked immunosorbent assay scores that represent the level of production of anti-Dsg3 IgG, body weight loss that reflects the severity of oral erosions and PV score that reflects the extent of skin lesions. We examined various immunosuppressive agents currently used to treat patients with PV model mice in preventive protocol. Cyclophosphamide almost completely suppressed the production of anti-Dsg3 IgG, development of body weight loss and the appearance of the PV phenotype in contrast with the control group without the drug. Azathioprine, cyclosporin A and tacrolimus hydrate also showed suppressive effects to various degrees. However, methylprednisolone and dexamethasone failed to show significant effects in contrast to the findings reported in humans. Knowing the advantages and limitations of this model will provide an important foundation for the future evaluation and development of novel therapeutic strategies.",
keywords = "Autoantibody, Evaluation, Immunosuppressive therapy, Mouse model, Pemphigus vulgaris",
author = "Yujiro Takae and Takeji Nishikawa and Masayuki Amagai",
year = "2009",
doi = "10.1111/j.1600-0625.2008.00776.x",
language = "English",
volume = "18",
pages = "252--260",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies

AU - Takae, Yujiro

AU - Nishikawa, Takeji

AU - Amagai, Masayuki

PY - 2009

Y1 - 2009

N2 - Pemphigus vulgaris (PV) is an autoimmune bullous disease caused by immunoglobulin G (IgG) autoantibodies against desmoglein 3 (Dsg3). We have generated an active disease mouse model for PV by adoptive transfer of Dsg3-/- lymphocytes. In this study, we investigated the benefits and limitations of this model as a tool to evaluate various immunosuppressive therapeutic strategies. We used the following three measurements to evaluate the effects of the drugs during the time course: Dsg3 enzymelinked immunosorbent assay scores that represent the level of production of anti-Dsg3 IgG, body weight loss that reflects the severity of oral erosions and PV score that reflects the extent of skin lesions. We examined various immunosuppressive agents currently used to treat patients with PV model mice in preventive protocol. Cyclophosphamide almost completely suppressed the production of anti-Dsg3 IgG, development of body weight loss and the appearance of the PV phenotype in contrast with the control group without the drug. Azathioprine, cyclosporin A and tacrolimus hydrate also showed suppressive effects to various degrees. However, methylprednisolone and dexamethasone failed to show significant effects in contrast to the findings reported in humans. Knowing the advantages and limitations of this model will provide an important foundation for the future evaluation and development of novel therapeutic strategies.

AB - Pemphigus vulgaris (PV) is an autoimmune bullous disease caused by immunoglobulin G (IgG) autoantibodies against desmoglein 3 (Dsg3). We have generated an active disease mouse model for PV by adoptive transfer of Dsg3-/- lymphocytes. In this study, we investigated the benefits and limitations of this model as a tool to evaluate various immunosuppressive therapeutic strategies. We used the following three measurements to evaluate the effects of the drugs during the time course: Dsg3 enzymelinked immunosorbent assay scores that represent the level of production of anti-Dsg3 IgG, body weight loss that reflects the severity of oral erosions and PV score that reflects the extent of skin lesions. We examined various immunosuppressive agents currently used to treat patients with PV model mice in preventive protocol. Cyclophosphamide almost completely suppressed the production of anti-Dsg3 IgG, development of body weight loss and the appearance of the PV phenotype in contrast with the control group without the drug. Azathioprine, cyclosporin A and tacrolimus hydrate also showed suppressive effects to various degrees. However, methylprednisolone and dexamethasone failed to show significant effects in contrast to the findings reported in humans. Knowing the advantages and limitations of this model will provide an important foundation for the future evaluation and development of novel therapeutic strategies.

KW - Autoantibody

KW - Evaluation

KW - Immunosuppressive therapy

KW - Mouse model

KW - Pemphigus vulgaris

UR - http://www.scopus.com/inward/record.url?scp=64549114217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549114217&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0625.2008.00776.x

DO - 10.1111/j.1600-0625.2008.00776.x

M3 - Article

C2 - 18643850

AN - SCOPUS:64549114217

VL - 18

SP - 252

EP - 260

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 3

ER -